Navigation Links
PSA Test Cut-off Could Signal Low-Risk Prostate Cancer
Date:2/16/2011

By Amanda Gardner
HealthDay Reporter

TUESDAY, Feb. 15 (HealthDay News) -- Men who have a low prostate-specific antigen (PSA) score when they're first tested may not need to be screened annually and probably don't need to undergo a biopsy, a new study suggests.

Dutch researchers presenting the findings at the Genitourinary Cancers Symposium in Orlando, Fla., said that few men with a PSA below 3.0 ng/ml were likely to develop prostate cancer and die of the disease.

"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies]," said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.

For this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years. Eighty percent of men in the group had PSA levels below that threshold.

In this group of men, the higher the PSA level at baseline, the more likely the person was to develop prostate cancer and to die of the disease. Only 1.8 percent of men with PSA scores below 1.0 were diagnosed with prostate cancer, with only 0.04 percent dying of the disease. This compares with 15.7 percent of those with scores from 2 percent to 2.9 percent developing a malignancy and 0.36 percent dying of the disease.

"This gives us some confidence that annual PSA screening is going to soon become a thing of the past," said Dr. Nicholas J. Vogelzang, chair of the Developmental Therapeutics Committee of US Oncology, who moderated the teleconference. "A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway."

A second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.

In comparison to men with low-risk, early-stage prostate cancer who took a placebo, "men randomized to receive Avodart saw their chance of progression significantly reduced, by approximately 40 percent," said study author Dr. Neil Fleshner, head of urology at the University Health Network and Love Chair in Prostate Cancer Prevention at Princess Margaret Hospital, both in Toronto. "Men with low-risk prostate cancer who want to have a period of observation should consider using this drug."

But the maker of Avodart (dutasteride), GlaxoSmithKline, is unlikely to apply for new approval to market the drug for what is essentially prevention, meaning it would be used off-label in this context, he added.

A final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure. In comparison with typical laparoscopic surgery, RALP offers surgeons three-dimensional vision and such improvements as better magnification and hand tremor filtering.

"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients," said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.

"The procedure is not as easy as manufacturers make it out to be, and enthusiasm in the U.S. needs to be tempered in terms of which hospitals should be buying the equipment and which surgeons should be doing these sorts of operations," he added.

One caution, though, is that the study only looked at three surgeons performing RALP.

More information

The National Cancer Institute has more on prostate cancer.

SOURCES: Feb. 15, 2011, teleconference with: Nicholas J. Vogelzang, M.D., chair and medical director, Developmental Therapeutics Committee, US Oncology; Monique Roobol, Ph.D., epidemiologist, department of urology, Erasmus University Medical Center, Rotterdam, the Netherlands; Neil Fleshner, M.D., head, urology, University Health Network and Love Chair in Prostate Cancer Prevention, Princess Margaret Hospital, Toronto; Prasanna Sooriakumaran, M.D., Ph.D., visiting fellow, urology, Weill Cornell Medical College, New York City; Feb. 15-17, 2011, presentations, Genitourinary Cancers Symposium, Orlando, Fla.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Premature Death Could Await Obese Kids
2. Six Other E. colis Could Be Lurking In Your Valentine Days Dinner
3. Tiny fruit fly could offer big clues in fight against obesity, researcher says
4. New Book Reveals How Qigong Could Be The Eastern Answer To Botox
5. Chocolate lovers could be lowering their risk of stroke: Study
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
8. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
9. Most maternal deaths in sub-Saharan Africa could be avoided
10. Dolphins could be ideal model to study human cervical cancer, UF veterinarians say
11. New Technology Could Widen Reach of Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PSA Test Cut-off Could Signal Low-Risk Prostate Cancer
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of ... Under the care of Maximized Living doctors at the London Olympics in 2012, ... Living is sending the largest contingent of elite chiropractors to Rio to support and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology: